Search Results
Aug 04, 2026, 07:00 ET Labcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancer
VENTANA® PTEN (SP218) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) to determine PTEN
More news about: Labcorp
Jun 11, 2026, 01:00 ET Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies
combined with a tyrosine kinase inhibitor (TKI).About the VENTANA MMR RxDx PanelThis IVDR approval for the VENTANA MMR RxDx Panel is a label expansion of Roche's current on-market panel. The VENTANA MMR RxDx Panel is intended for the assessment of expression of MMR proteins in formalin-fixed,
More news about: Roche
Jun 11, 2026, 01:00 ET Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies
combined with a tyrosine kinase inhibitor (TKI).About the VENTANA MMR RxDx PanelThis IVDR approval for the VENTANA MMR RxDx Panel is a label expansion of Roche's current on-market panel. The VENTANA MMR RxDx Panel is intended for the assessment of expression of MMR proteins in formalin-fixed,
More news about: Roche
Jan 08, 2026, 10:30 ET VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses
demonstrating moderate to strong membranous CLDN18.2 immunohistochemical staining.Astellas collaborated with Roche on the Ventana™ CLDN18 (43-14a) RXDX assay which, where approved, can be used by pathologists or laboratories to identify patients eligible for targeted treatment with zolbetuximab. About
More news about: Astellas Pharma Inc.
Dec 10, 2025, 18:30 ET Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
patient group that could benefit from targeted first-line therapy.1,2Astellas collaborated with Roche on the Ventana™ CLDN18 (43-14a) RXDX assay, which, where approved, can be used by pathologists or laboratories to identify patients eligible for targeted treatment with VYLOY (zolbetuximab).Astellas
More news about: Astellas Pharma Inc.